Company intelligence / Profile preview

Sistema

Moscow, Moscow region, Russia
Ownership
Private
Development stage
Other
01

Overview

Sistema-BioTech has developed a proprietary technology for producing recombinant therapeutic proteins using CHO cell systems that achieves significantly higher protein yields compared to imported technologies used in Russia. The company developed COVID-19 diagnostic test systems, with over 7 million tests performed by mid-November 2021. They created a highly effective producer cell line for Adalimumab, a monoclonal antibody listed in Russia's vital and essential medicines (VED) list.

Therapeutic areas
ImmunologyWomen's HealthNeurologyDermatologyInfectious DiseasesGastroenterologyOncology
Modalities
Recombinant proteinMonoclonal antibody
Industry
Biotech
02

Drug pipeline

2 assets

adalimumab biosimilar (Sistema)

Preclinical

1 more asset in the full pipeline.

Request access →
03

Partnerships

CapitalBio TechnologyRussia-China Investment Fund (RCIF)Dr. Reddy's

Beyond the preview

Go deeper on Sistema.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sistema.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call